Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis

NCT00316602 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT00316602
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00316602 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Controlled Phase II Study to Evaluate Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in 18-40 Year Old Subjects With Diagnosed Atopic Dermatitis
Lead sponsor
Bavarian Nordic
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2006
Completion date
April 30, 2010
Enrollment
632 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis